Celea, a biotech startup launched by PureTech Health, has emerged from stealth with $180 million in Series A financing to advance a new drug for idiopathic pulmonary fibrosis (IPF), a chronic lung disease with limited treatment options. The company claims its therapy is an improved version of Roche's Esbriet, the current standard of care, but offers a better safety and tolerability profile.
The funding round was co-led by RA Capital Management and Leaps by Bayer, with participation from other undisclosed investors. The proceeds will support Celea's lead candidate, CE-101, through Phase 2 clinical trials. IPF affects about 100,000 people in the U.S. and has a median survival of 3-5 years from diagnosis.
Details on CE-101's mechanism and specific clinical data remain sparse, as the drug has not yet entered human trials. The company plans to file an investigational new drug application with the FDA in 2024, with Phase 1 studies expected to begin shortly thereafter. A clear regulatory pathway and PDUFA date are years away.
PureTech's stock saw modest gains on the news, though the company's market cap remains under $1 billion. The IPF treatment market, currently dominated by Roche's Esbriet and Boehringer Ingelheim's Ofev, is valued at roughly $3 billion annually. Celea will need to demonstrate meaningful differentiation to capture market share from well-established rivals.
Patient advocates welcome the potential for new options but caution that many experimental IPF drugs have failed in late-stage trials due to toxicity or lack of efficacy. Without human data, Celea's claim of superiority remains theoretical. The company's ability to execute on clinical development will determine whether this well-funded bet pays off.